Resverlogix(TSX) RVX

Market CapCA$32.67M

Since IPO (2003)-94%

5 Year-86%

1 Year-5%

1 Month+6%

CA$0.10

-5.00%

-0.01Today

Resverlogix last closing stock price
Metric	Price	Date
Last close	CAD 0.10	2026-07-31

Resverlogix stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-9.52%	CAD 0.11	2026-07-24
1 month	+5.56%	CAD 0.09	2026-06-30
3 month	-5%	CAD 0.10	2026-05-01
Year to date	-5%	CAD 0.10	2025-12-31
1 year	-5%	CAD 0.10	2025-07-31
3 year	-13.64%	CAD 0.11	2023-08-01
5 year	-85.82%	CAD 0.67	2021-07-30
Since inception	-93.87%	CAD 1.55	2003-04-25

Resverlogix Financials at a Glance

Market Cap

CA$32.67M

Revenue (TTM)

$0.00

Net Income (TTM)

-$6.52M

EPS (TTM)

-CA$0.03

P/E Ratio

-3.25

Dividend

CA$0.00

Beta (Volatility)

-0.01 (Low)

Dividend

CA$0.00

Beta (Volatility)

-0.01 (Low)

Price

CA$0.10

Volume

14,943

Open

CA$0.10

Price

CA$0.10

Volume

14,943

Open

CA$0.10

Previous Close

CA$0.10

Daily Range

CA$0.10 - CA$0.10

52-Week Range

CA$0.09 - CA$0.15

Estimated Earnings Date

Aug 13, 2026

Dividend

CA$0.00

Beta (Volatility)

-0.01 (Low)

Price

CA$0.10

Volume

14,943

Open

CA$0.10

Previous Close

CA$0.10

Daily Range

CA$0.10 - CA$0.10

52-Week Range

CA$0.09 - CA$0.15

Estimated Earnings Date

Aug 13, 2026

RVX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Resverlogix

Resverlogix Corp. is a biotechnology firm focused on developing innovative treatments for diseases with limited existing solutions. The company is advancing its lead compound, apabetalone, through pivotal Phase III clinical trials targeting cardiovascular disease, diabetes, kidney disease, and neurodegenerative disorders.

Products and Services

Apabetalone (RVX-208) for various chronic diseases
Collaboration with Eversana for COVID-19 treatment rollout
Research and development in biotechnology and therapeutics

Growth Outlook

Apabetalone is in pivotal Phase III trials, indicating significant progress
Partnership with Eversana enhances market access and distribution capabilities
Focus on unmet medical needs positions the company for future growth

Financial Highlights

Recent quarterly net income of -$3.39 million reflects ongoing R&D investments
Trailing twelve months (TTM) revenue remains at $0, emphasizing early-stage development
Cash and cash equivalents of $50,034 as of March 31, 2026, indicate liquidity challenges

AI Generated • Jul 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Donald J. McCaffrey

Website

www.resverlogix.com

Headquarters

Calgary, AB T3E 6L1, CA

RVX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

6.67%

Return on Capital

N/A

Return on Assets

-81.57%

Earnings Yield

-30.77%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$32.67M

Shares Outstanding

343.92M

Volume

14.94K

Avg. Volume

32.13K

Financials (TTM)

Gross Profit

-$487.49K

Operating Income

-$5.15M

EBITDA

-$3.40M

Operating Cash Flow

-$3.72M

Capital Expenditure

-$409.16K

Free Cash Flow

-$3.93M

Cash & ST Invst.

$50.03K

Total Debt

$75.06M

Resverlogix Performance Analysis

Resverlogix annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Resverlogix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Resverlogix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.02	-85.7%
2023	2023-12-31	USD -0.08	352.4%
2024	2024-12-31	USD -0.04	-54.8%
2025	2025-12-31	USD -0.04	0.8%

Resverlogix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	61.0%
Q3	2025-09-30	41.0%
Q4	2025-12-31	84.8%
Q1	2026-03-31	-1514.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$78.69K

+47.3%

Gross Margin

0.00%

N/A

Market Cap

CA$32.67M

N/A

Market Cap/Employee

CA$1.92M

N/A

Employees

N/A

Net Income

-$3.39M

+32.1%

EBITDA

-$1.08M

-6.5%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$50.03K

-67.3%

Total Debt

$75.06M

+327.0%

Accounts Receivable

$855.60K

+31.8%

Inventory

$435.31K

-53.5%

Long Term Debt

$53.24M

+554.7%

Short Term Debt

$21.82M

+131.0%

Return on Assets

-81.57%

N/A

Return on Invested Capital

14.20%

N/A

Free Cash Flow

-$972.79K

+16.2%

Operating Cash Flow

-$972.79K

-4.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

LABS.TOMediPharm Labs Corp.

LABS.TOMediPharm Labs Corp.CA$0.08+0.00%

MBX.TOMicrobix Biosystems Inc.

MBX.TOMicrobix Biosystems Inc.CA$0.30-1.67%

AVCN.TOAvicanna Inc.

AVCN.TOAvicanna Inc.CA$0.13+0.00%

BCT.TOBriaCell Therapeutics Corp.

BCT.TOBriaCell Therapeutics Corp.CA$4.82-5.49%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$9.36+0.02%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$23.99+0.01%

PLTRPalantir Technologies

PLTRPalantir Technologies$125.65+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$67.96+0.05%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$41.43-0.05%

INTCIntel

INTCIntel$91.00+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.81+0.07%

Questions About RVX

What is the current price of Resverlogix?

Resverlogix is trading at CA$0.10 per share.

What is the 52-week range for Resverlogix?

Over the past 52 weeks, Resverlogix has traded between CA$0.09 and CA$0.15.

How much debt does Resverlogix have?

As of the most recent reporting period, Resverlogix reported total debt of $104.67M.

How much cash does Resverlogix have on hand?

Resverlogix reported $69.78K in cash and cash equivalents in its most recent financial results.

What is Resverlogix’s dividend yield?

Resverlogix does not currently have a dividend yield.

Resverlogix(TSX) RVX

Resverlogix Financials at a Glance

RVX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Resverlogix

RVX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Resverlogix Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RVX

What is the current price of Resverlogix?

What is the 52-week range for Resverlogix?

How much debt does Resverlogix have?

How much cash does Resverlogix have on hand?

What is Resverlogix’s dividend yield?

Premium Investing Services